Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab Vedotin”

187 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 187 results

Testing effectiveness (Phase 2)Study completedNCT00051597
What this trial is testing

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Who this might be right for
Hodgkin DiseaseLymphoma, Large-CellSarcoma, Kaposi+2 more
Seagen Inc. 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03057795
What this trial is testing

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 62
Testing effectiveness (Phase 2)Study completedNCT01492088
What this trial is testing

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Anaplastic Large-cell Lymphoma
Millennium Pharmaceuticals, Inc. 36
Testing effectiveness (Phase 2)Looking for participantsNCT03356054
What this trial is testing

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Who this might be right for
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Testing effectiveness (Phase 2)Study completedNCT03222492
What this trial is testing

Brentuximab Vedotin for Systemic Sclerosis

Who this might be right for
Diffuse Cutaneous Systemic SclerosisSclerodermadcSSc
National Institute of Allergy and Infectious Diseases (NIAID) 17
Testing effectiveness (Phase 2)Study completedNCT01851200
What this trial is testing

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Who this might be right for
Germ Cell Cancer
Fondazione Michelangelo 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734771
What this trial is testing

Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Patrick Reagan 24
Not applicableStudy completedNCT01578967
What this trial is testing

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma, Adult
UNC Lineberger Comprehensive Cancer Center 41
Testing effectiveness (Phase 2)UnknownNCT06201507
What this trial is testing

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma
Beijing Children's Hospital 44
Early research (Phase 1)Study completedNCT01596218
What this trial is testing

Brentuximab Vedotin for Steroid Refractory GvHD

Who this might be right for
Graft vs. Host Disease
Massachusetts General Hospital 35
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Study completedNCT01421667
What this trial is testing

Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin+1 more
Seagen Inc. 176
Testing effectiveness (Phase 2)Looking for participantsNCT07002216
What this trial is testing

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Who this might be right for
Hodgkin LymphomaAdvanced Hodgkin Lymphoma
University of Miami 48
Early research (Phase 1)Study completedNCT02164006
What this trial is testing

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Who this might be right for
Hodgkin's Lymphoma
TG Therapeutics, Inc. 16
Not applicableStudy completedNCT01868451
What this trial is testing

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center 118
Early research (Phase 1)WithdrawnNCT03373305
What this trial is testing

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Who this might be right for
CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis FungoidesRecurrent Mycosis Fungoides+4 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT02388490
What this trial is testing

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

Who this might be right for
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Seoul National University Hospital 25
Testing effectiveness (Phase 2)Ended earlyNCT03947255
What this trial is testing

Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Who this might be right for
Hodgkin LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell Lymphoma
Seagen Inc. 12
Post-approval studies (Phase 4)Study completedNCT01990534
What this trial is testing

Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Millennium Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03007030
What this trial is testing

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Who this might be right for
CD30-Positive Neoplastic Cells PresentMalignant Mesothelioma
M.D. Anderson Cancer Center 25
Next Page